TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A real-world study of 186 attendees at a brain health service in Monza, Italy, found that many people reporting memory changes despite normal standard test performance had modifiable dementia risk factors. Among participants with subjective cognitive decline, p-Tau217 above the study threshold was linked to signs of neurodegeneration; about 60% of those who received results said they felt more motivated to make lifestyle changes.
A study of 186 people attending a brain health service in Monza, Italy, found a substantial burden of modifiable dementia risk factors among participants who reported cognitive changes but did not show impairment on standard tests. The researchers also linked p-Tau217 levels above a study threshold to early signs of neurodegeneration in some participants, while about 60% of those given biomarker results and estimated risk said they felt more motivated to change their lifestyle.
The study, published in Neurological Sciences, included 132 people with subjective cognitive decline (SCD) among 186 consecutive attendees. SCD describes people who notice changes in memory or other thinking abilities while continuing to perform normally on standard cognitive tests. The researchers examined clinical, biological and imaging information collected through the service, which is organized around brain-health risk assessment and prevention rather than diagnosis alone.
For SCD participants with available blood tests, the researchers grouped results according to plasma p-Tau217, a biomarker associated with Alzheimer’s-related changes. They classified participants as A+ when the result was at or above 0.15 picograms per milliliter, and A- when it was below that threshold. The report says the A+ group showed signs of neurodegeneration; a biomarker result does not, by itself, establish that a person will develop dementia.
At a second visit, participants were told their p-Tau217 and APOE genotype results and given an estimate of dementia risk. The researchers calculated risk using relative-risk information from the Lancet Commission and a baseline based on the Brookmeyer method and Italian mortality data. Preventive measures were recommended, and participants were surveyed online one week later. About 60% of those who underwent disclosure reported greater motivation for lifestyle changes, according to the report.
What Risk Disclosure May Change
The findings highlight a potential gap between subjective memory concerns and standard test performance. A normal result on a cognitive screening test does not explain every concern, while the study suggests that some people who report changes may also have health or lifestyle factors associated with dementia risk. That makes careful assessment relevant even when tests do not show clear impairment.
The disclosure results also offer an early indication that personalized risk information may affect how people think about prevention. However, the study measured self-reported motivation one week later, not whether participants made lasting changes or whether those changes reduced dementia risk. Its results therefore support further study of communication approaches, not a conclusion that biomarker disclosure improves health outcomes.
For readers, the distinction between risk and diagnosis matters. A biomarker finding can contribute information to a broader clinical assessment, but the report does not establish that every person with SCD or an elevated p-Tau217 result has Alzheimer’s disease. Decisions about testing and interpreting results require clinical context.
As an affiliate, we earn on qualifying purchases.
How Brain Health Services Assess Risk
SCD is common and has varied causes. Some people with these concerns may have early biological changes associated with Alzheimer’s, while others may have different neurodegenerative or non-neurodegenerative explanations. The study’s authors note that earlier research has suggested that up to one-third of people with SCD may have preclinical Alzheimer’s disease in some settings; that figure is not a finding about this Monza sample.
Brain health services in Europe are designed to assess and reduce dementia risk. Depending on the service, assessments can include cognitive screening, blood biomarkers such as p-Tau217, genetic information and brain imaging. The Monza study also considered other attendee groups, including people with mild cognitive impairment, functional cognitive decline and people worried about their cognition without identified impairment. The researchers described differences among these groups, but cautioned that this part of the analysis was exploratory because of the small group sizes.
There is continuing debate over biomarker testing in people whose cognitive performance remains normal. The source report says the Alzheimer’s Association workgroup recommends against diagnostic biomarker testing in cognitively unimpaired people outside observational or therapeutic research. The International Working Group generally frames biomarker-positive people without impairment as being at risk, while allowing non-diagnostic testing pathways for some people with SCD. These positions reflect different approaches to how biological risk should be named and communicated.
“Structured disclosure of biomarker results and risk estimates was well accepted, and about 60% of participants who underwent disclosure reported greater motivation for lifestyle changes.”
— The study authors, as summarized by News-Medical
As an affiliate, we earn on qualifying purchases.
Limits of the Monza Findings
The report describes a single brain health service and a real-world group of attendees, so the findings may not represent all people with memory concerns or the wider population. The available source summary does not provide detailed counts for every biomarker subgroup or the full range of measured risk factors, limiting how precisely those results can be compared.
It is also unclear whether the reported motivation led to sustained lifestyle changes. Participants completed follow-up questionnaires one week after receiving their results, and the summary does not report longer-term behavior, cognitive outcomes or dementia diagnoses. The study does not establish that p-Tau217 results caused the reported motivation or that disclosure itself reduces future risk.
More broadly, the clinical meaning of biomarker testing in people who perform normally on cognitive tests remains debated. A threshold used to categorize study participants is not, on its own, a universal diagnosis rule. The source material does not provide enough detail to determine how the findings should change testing or counseling outside the service.
As an affiliate, we earn on qualifying purchases.
Longer Follow-Up Is Needed
The report does not identify a planned next study or a specific follow-up date. To clarify the findings, further research would need to test whether responses to disclosure persist beyond the first week and whether reported motivation translates into measurable lifestyle changes. Larger studies across different services and populations could also show how common the observed risk patterns are.
For now, the study adds real-world evidence to discussion about how to assess and communicate risk for people who report memory changes despite normal test performance. Anyone concerned about changes in memory should discuss them with a qualified health professional, who can consider the person’s symptoms, health history and whether further evaluation is appropriate.
dementia prevention lifestyle guide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is subjective cognitive decline?
Subjective cognitive decline means a person notices changes in memory or thinking, while standard cognitive tests do not show clear impairment. It can have different causes and does not by itself mean someone has dementia.
What did the study find about p-Tau217?
Among SCD participants with available blood tests, the researchers classified p-Tau217 results at or above 0.15 pg/mL as A+. The report linked elevated results to signs of neurodegeneration, but does not say that this result alone diagnoses Alzheimer’s disease or predicts an individual outcome.
Did receiving biomarker results lead to lifestyle changes?
About 60% of participants who received disclosure reported greater motivation to make lifestyle changes in a questionnaire one week later. The study summary does not establish whether they made lasting changes or whether those changes affected dementia risk.
Does a normal cognitive test rule out a problem?
The study concerns people who reported changes despite normal performance on standard tests, so a normal test does not necessarily explain every concern. A clinician can assess symptoms and decide whether further evaluation is appropriate; the study does not provide a personal diagnosis.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
